Baseline analysis of patients enrolled in the BERING CRC study

BRAF V600E-mutant metastatic colorectal cancer (mCRC) is characterized by a poor prognosis and limited clinical data. Sebastian Stintzing, MD, Charite University Hospital, Berlin, Germany, discusses the results of a baseline analysis of patients enrolled in the BERING CRC study (NCT04673955), a European real-world study in patients with BRAF V600E-mutant mCRC. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.